SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123689
Filing Date
2024-11-08
Accepted
2024-11-08 07:30:25
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20240930.htm   iXBRL 10-Q 2847299
2 EX-31.1 akro-ex31_1.htm EX-31.1 16359
3 EX-31.2 akro-ex31_2.htm EX-31.2 16101
4 EX-32.1 akro-ex32_1.htm EX-32.1 13601
  Complete submission text file 0000950170-24-123689.txt   10666235

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT akro-20240930.xsd EX-101.SCH 1309412
69 EXTRACTED XBRL INSTANCE DOCUMENT akro-20240930_htm.xml XML 2031392
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 241438013
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)